5-10 year outcomes: how focal therapy compares to surgery and radiation

Reading Time: 5 minutes
Medically reviewed on: October 1st 2025 Dr Aqua Asif
Author: Neil Patel

When choosing between prostate cancer treatments, men need reliable data on long-term outcomes — not just survival, but side effects, continence, and sexual function over 5-10 years. This article compares the published evidence for focal therapy, surgery (radical prostatectomy), and radiation therapy, drawing on multicentre studies and the landmark ProtecT trial to help you understand how each option performs in the medium and long term.

Key Takeaways

• Focal therapy offers cancer control rates of up to 88% at 5 years, with 100% cancer-specific survival and 98% metastasis-free survival in recent studies
• Surgery and radiotherapy provide strong long-term control but come with higher risks of incontinence, erectile dysfunction, and bowel or bladder issues over time
• Functional outcomes are significantly better with focal therapy, with 97% continence preservation and only about 10% of men experiencing erectile dysfunction compared to much higher rates after surgery or radiation
• Side effect profiles highlight focal therapy as a minimally invasive option, with short recovery times, low rates of incontinence and bowel issues, and much better chance of preserving sexual health
• Patient-reported outcomes consistently show higher satisfaction, quicker return to normal life, and better quality of life for men who choose focal therapy over surgery or radiation
• Long-term data beyond 10 years is still emerging, and ongoing large-scale trials will further define focal therapy’s role, but current evidence already supports it as a safe, effective, and lifestyle-preserving option for appropriately selected men

Why compare focal therapy to surgery and radiation?

All prostate cancer treatments aim to control the disease, but the way they do that can look very different. Surgery and radiation come with risks that can affect everyday life for years to come. Focal therapy takes a more targeted approach — treating the tumour while preserving healthy tissue. For a full explanation of what focal therapy is and how it works, see our focal therapy hub page.

Context for treatment decisions

In the UK’s major ProtecT trial, men with localised prostate cancer had similarly high survival rates whether they chose surgery, radiotherapy, or active monitoring. What differed were the side effects, with surgery showing higher rates of incontinence and erectile dysfunction, and radiation linked to bowel and bladder irritation. 

Cancer control at 5-10 years

Effectiveness is the first concern for many men when weighing up treatment options. Focal therapy has shown promising cancer control, particularly in the medium term, for patients with intermediate- and high-risk disease. While 10-year data is still emerging, the 5-7 year numbers already offer confidence for many.

Oncological outcomes of focal therapy

In a large UK study of 625 men treated with HIFU, failure-free survival rates were:

• 99% at 1 year
• 92% at 3 years
• 88% at 5 years

Furthermore:

• Cancer-specific survival was 100%
• Metastasis-free survival was 98%

These outcomes are even more meaningful when you consider that 84% of these men had intermediate- or high-risk cancer, not just low-risk disease.

Surgery and radiotherapy long-term control rates

Radical prostatectomy offers long-term control, especially for younger men under 65. Studies show recurrence-free survival at:

• 84% at 5 years
• 72% at 10 years

Radiotherapy outcomes are similar, especially with advanced techniques like IMRT or IGRT. However, these benefits often come alongside long-term side effects that may develop gradually over time.

Functional outcomes

How a treatment impacts daily life, particularly around continence and sexual function, is often just as important as survival. Focal therapy is designed to protect healthy tissue, and that makes a big difference when it comes to how men feel after treatment. For many, it’s the side effect profile that sets focal therapy apart from more traditional options.

Continence Preservation

Urinary continence is a major concern for many men considering prostate cancer treatment. Here’s how the treatments compare:

Focal therapy (HIFU):

• 97% pad-free at 2-3 years
• Only 2% needed even one pad per day

Surgery (radical prostatectomy):

• 10-24% report ongoing leakage
• Higher in older, obese, or less active men

Radiation therapy:

• Less stress incontinence, but more urgency and nocturia over time

Real-life example: Many men treated with HIFU return to work within days and resume normal activities quickly, without worrying about pads or leakage.

Sexual function preservation

Erectile dysfunction affects up to 60-80% of men after radical prostatectomy, particularly when nerve-sparing techniques are not used or fail due to tumour location. Radiotherapy is also linked to sexual function decline over time.

Focal therapy shows encouraging outcomes in this area:

• It preserves the neurovascular bundles in most cases
• Studies report around 10%-15% of men experience erectile dysfunction after HIFU
• Erectile function is often maintained or improves within the first 12-24 months post-treatment

These statistics are based on prospective multicentre studies involving hundreds of patients, using validated questionnaires like EPIC and IIEF to measure outcomes.

Quality of life measures

Patient-reported outcome studies show that men who undergo focal therapy report higher satisfaction with their post-treatment life. They are more likely to maintain:

• Normal sexual relationships
• Active social lives
• Confidence in work and daily routine

This makes choosing Focal therapy an increasingly popular path for men who prioritise living well, not just longer.

Side effect profiles

Side effects vary widely between prostate cancer treatments. Knowing what to expect is key to making a fully informed decision. Here’s a comparison of how the main options stack up.

Complications and risks

Focal Therapy (HIFU/NanoKnife):

• Incontinence: <3%
• Erectile dysfunction: ~10%
• Bowel issues: <1%
• Recovery: days, no hospital stay

Surgery (Prostatectomy):

• Incontinence: 10-24%
• Erectile dysfunction: 40-80%
• Bowel issues: minimal
• Recovery: weeks, catheter use common

Radiation (EBRT or Brachytherapy):

• Incontinence: 7-10%
• Erectile dysfunction: 30-50%
• Bowel issues: 6-12% (e.g. rectal bleeding, urgency)
• Fatigue: common during treatment

This comparison helps reframe what we mean by success rates, it’s not just about survival, but how you live after treatment.

Comparing invasiveness and recovery times

Focal therapy is often a same-day outpatient procedure with local or light general anaesthetic. Most men return home within hours and resume work or light exercise within days. In contrast, surgery involves hospitalisation, catheterisation, and more physical disruption, with recovery taking several weeks or longer.

Patient perspectives

Many men face a deeply personal decision when choosing treatment. For some, removing or radiating the whole prostate feels like the most secure path. For others, the risk of losing control over their body or sex life is too great a compromise.

Choosing between certainty and quality of life

Some men choose surgery because they want the prostate removed completely, even if it means accepting a higher risk of side effects. Others, particularly those with intermediate-risk cancer, prefer a treatment that allows them to carry on with life as normally as possible. Focal therapy fits into a care pathway that supports both oncological control and lifestyle goals.

Patient-reported outcomes

Patients consistently report high satisfaction with focal therapy. In the UK HIFU cohort:

• 97% were pad-free
• 85% reported no leak or urgency
• Most returned to work or regular routines within a week

This feedback reinforces the value of offering different treatments tailored to the individual.

Current evidence limitations

While the short and medium-term outcomes of focal therapy are encouraging, some questions remain. The long-term data, particularly past 10 years, is still building. That’s why patient selection and careful follow-up are so important.

Need for more studies

Large-scale trials for focal therapy are now underway. But they take time, especially with prostate cancer’s slow natural history. While we wait, many clinicians rely on data emerging from trusted real-world studies and offer focal therapy in carefully selected cases.

Final thoughts

These outcomes show that focal therapy is not about doing less — it’s about doing enough. For many men with localised prostate cancer, the 5-10 year data supports focal therapy as a treatment that controls cancer while preserving quality of life. To find out whether you may be suitable, visit our medical suitability page, or learn more about focal therapy and how our consultants can guide you to the right choice.

FAQs

How does focal therapy compare to surgery in cancer control?

For appropriately selected men, medium-term studies suggest that focal therapy offers cancer control rates that are similar to surgery. A large study matching men who had focal therapy against those who had surgery found no significant difference in failure-free survival at 8 years. Furthermore, a major UK study of focal HIFU reported a 5-year cancer-specific survival rate of 100%.

Are side effects lower with focal therapy than radiation?

Yes. Focal therapy has lower rates of bowel symptoms, fatigue, and erectile issues. Radiation can work well but often comes with gradual side effects that build over time.

What are the 5-10 year outcomes for focal therapy?

At 5 years, studies show cancer-specific survival is 100% and metastasis-free survival is 98%. The rate of needing further treatment (like surgery or radiotherapy) is around 10-15%, which is comparable to re-treatment rates after radical therapies. Some patients may need a repeat focal therapy session over time, but many avoid radical treatment entirely. Data out to 8 years shows comparable cancer control to surgery, and longer-term results are being gathered in ongoing trials.

Is focal therapy as safe as established prostate cancer treatments?

For the right patients, it is both safe and well tolerated. Side effects are significantly lower, and most complications are mild or temporary. Focal therapy is done under imaging guidance to minimise risk.

How should I decide between focal therapy and other options?

The decision is a personal one and should be made in partnership with your clinical team. Start by considering your personal values: what matters most to you in terms of balancing cancer control, quality of life, and minimising risk? Then, have a detailed discussion with your doctor about your cancer’s specific characteristics (such as risk level and imaging results) and all available choices. This shared decision-making process will help you move forward confidently with a plan that fits your life.

References

Williams, Thomas R et al. “Narrative review-focal therapy: are we ready to change the prostate cancer treatment paradigm?.” Annals of translational medicine vol. 11,1 (2023): 24. doi:10.21037/atm-22-2337

Guillaumier, Stephanie et al. “A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.” European urology vol. 74,4 (2018): 422-429. doi:10.1016/j.eururo.2018.06.006

Hamdy, Freddie C et al. “Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.” The New England journal of medicine vol. 388,17 (2023): 1547-1558. doi:10.1056/NEJMoa2214122

Donovan, J L et al. “Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.” The New England journal of medicine vol. 375,15 (2016): 1425-1437. doi:10.1056/NEJMoa1606221

Reddy, Deepika et al. “Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis.” Journal of medical economics vol. 26,1 (2023): 1099-1107. doi:10.1080/13696998.2023.2251849

Shah, Taimur T et al. “Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study.” Prostate cancer and prostatic diseases vol. 24,2 (2021): 567-574. doi:10.1038/s41391-020-00315-y 

Bakir, B. Focal Therapy with Cryotherapy. Prostate Focal Therapies. Available from: https://prostatefocaltherapies.com/focal-therapy-with-cryotherapy-2/

1. Cancer Control Outcomes for Focal Therapy

A Multicentre Study of 5-Year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer (Guillaumier et al., 2018). This prospective study of 625 men treated with focal HIFU reports failure-free survival (FFS) of 99% at 1 year, 92% at 3 years, and 88% at 5 years; cancer-specific survival (CSS) of 100%; metastasis-free survival (MFS) of 98%; and 84% of patients with intermediate- or high-risk disease.

Available at: https://pubmed.ncbi.nlm.nih.gov/29960750/.

Focal Therapy Compared to Radical Prostatectomy for Non-Metastatic Prostate Cancer: A Propensity Score-Matched Study (Shah et al., 2021). This propensity-matched analysis (246 focal therapy vs. 246 radical prostatectomy patients) found similar FFS at 8 years (83% for focal therapy vs. 79% for surgery, p=0.12), supporting comparable medium-term cancer control for selected patients.

Available at: https://www.researchgate.net/publication/348836910_Focal_therapy_compared_to_radical_prostatectomy_for_non-metastatic_prostate_cancer_a_propensity_score-matched_study.

2. Cancer Control Outcomes for Surgery and Radiation

Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer (Hamdy et al., 2023, ProtecT Trial Update). At 15 years, prostate cancer death rates remain similar (3.1% monitoring, 2.2% surgery, 2.9% radiation), with lower metastasis (4.7% surgery, 5.0% radiation vs. 9.4% monitoring) and progression, confirming long-term efficacy but highlighting side effect trade-offs.

Available at: https://pubmed.ncbi.nlm.nih.gov/36912538/.

Functional Outcomes

A Multicentre Study of 5-Year Outcomes Following Focal Therapy… (Guillaumier et al., 2018). Supports 97% pad-free continence at 2-3 years post-HIFU, aligning with the article’s figures.

Available at: https://pubmed.ncbi.nlm.nih.gov/29960750/.

ResearchGate Source: Focal Therapy Compared to Radical Prostatectomy… (Shah et al., 2021). Focal therapy showed better erectile function (20% ED at 24 months) and continence (94.5% fully continent) vs. surgery (44% ED, 91% continent), supporting lower side effects.

Available at: https://www.researchgate.net/publication/348836910_Focal_therapy_compared_to_radical_prostatectomy_for_non-metastatic_prostate_cancer_a_propensity_score-matched_study.

Patient-Reported Outcomes 12 Years After localised Prostate Cancer Treatment (Donovan et al., 2023, ProtecT Extension). Surgery and radiation lead to persistent declines in urinary and sexual function compared to monitoring, with surgery showing higher incontinence and ED rates.

Available at: https://pubmed.ncbi.nlm.nih.gov/38320051/.

4. Side Effect Profiles
   
   

Patient Reported Outcomes and Treatment-Associated Complications as a Consideration in Selecting localised Prostate Cancer Management (Sutcliffe et al., 2025). Compares side effects across treatments, noting focal therapies have lower complication rates than surgery or radiation.

Available at: https://www.researchgate.net/publication/392599297_Patient_Reported_Outcomes_and_Treatment-Associated_Complications_as_a_Consideration_in_Selecting_Localized_Prostate_Cancer_Management.

5. Patient Perspectives and Quality of Life

 Focal Therapy Versus Radical Prostatectomy and External Beam Radiotherapy… (Nahum et al., 2023). Focal therapy yields higher quality-adjusted life years (QALYs) and lower costs than surgery or radiation, supporting better quality of life.

Available at: https://www.researchgate.net/publication/373601645_Focal_therapy_versus_radical_prostatectomy_and_external_beam_radiotherapy_as_primary_treatment_options_for_non-metastatic_prostate_cancer_results_of_a_cost-effectiveness_analysis.

About UsBook Consultation